Zheng Yang, Gao Dengyu, Xie Hongyang, Geng Huafeng
Department of Gynecology, China-Japan Union Hospital of Jilin University, 126 Sendai Street, Changchun, Jilin 130033, China.
Department of Anesthesiology, China-Japan Union Hospital of Jilin University, 126 Sendai Street, Changchun, Jilin 130033, China.
Cell Signal. 2025 Mar;127:111609. doi: 10.1016/j.cellsig.2025.111609. Epub 2025 Jan 16.
Allergic asthma is a chronic airway inflammatory reaction that seriously affects people's quality of life and even endangers their lives. The aim of this study was to explore the role of epicatechin (EC) on asthma and its potential mechanism. A mice model of allergic asthma was established by intraperitoneal injection of ovalbumin (OVA) with aluminum hydrogen solution, and nebulized inhalation of OVA to stimulate. EC (10, 20, 40 mg/kg) was administered 30 min before nebulization for three consecutive days. The results showed that EC attenuated OVA-induced lung injury, inflammatory cell infiltration, IgE, and inflammatory cytokine production. EC also inhibited OVA-induced NF-κB activation and increased Nrf2 and HO-1 expression. 16S rRNA sequencing analysis demonstrated that at genus level, EC significantly increased the abundance of Lachnospiraceae_NK4A136_group, Ligilactobacillus, Alloprevotella. Meanwhile, EC inhibited the abundance of Clostridia UCG-014, Helicobacter, Paramuribaculum, and Escherichia-Shigella. In conclusion, EC can effectively alleviate the symptoms of asthma in mice, which may through regulating the composition of gut microbiota and inhibiting inflammatory response.
过敏性哮喘是一种慢性气道炎症反应,严重影响人们的生活质量,甚至危及生命。本研究旨在探讨表儿茶素(EC)对哮喘的作用及其潜在机制。通过腹腔注射卵清蛋白(OVA)和氢氧化铝溶液建立过敏性哮喘小鼠模型,并通过雾化吸入OVA进行刺激。在雾化前30分钟连续三天给予EC(10、20、40mg/kg)。结果表明,EC减轻了OVA诱导的肺损伤、炎症细胞浸润、IgE和炎性细胞因子的产生。EC还抑制了OVA诱导的NF-κB活化,并增加了Nrf2和HO-1的表达。16S rRNA测序分析表明,在属水平上,EC显著增加了毛螺菌科_NK4A136_组、 Ligilactobacillus、Alloprevotella的丰度。同时,EC抑制了梭菌属UCG-014、幽门螺杆菌、副 Muribaculum和大肠埃希菌-志贺菌属的丰度。总之,EC可以有效缓解小鼠哮喘症状,这可能是通过调节肠道微生物群的组成和抑制炎症反应来实现的。
Int Immunopharmacol. 2017-3
Eur J Pharmacol. 2017-7-18
Int Immunopharmacol. 2017-8-30